The regulatory environment in 2025 is more complex than ever. The FDA (US) and EMA (EU) have introduced fast-track designations for "Breakthrough" respiratory therapies, but they have also increased scrutiny on "Generic Bioequivalence." For a generic inhaler to be approved, it must prove that the drug particles reach the exact same depth in the lungs as the branded version—a high...